Provided by Tiger Trade Technology Pte. Ltd.

iHuman

1.81
0.0000
Post-market: 1.810.00000.00%16:10 EST
Volume:2.72K
Turnover:4.95K
Market Cap:92.93M
PE:6.32
High:1.83
Open:1.83
Low:1.81
Close:1.81
52wk High:3.60
52wk Low:1.69
Shares:51.34M
Float Shares:14.72M
Volume Ratio:0.17
T/O Rate:0.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2862
EPS(LYR):0.2466
ROE:11.15%
ROA:3.26%
PB:0.66
PE(LYR):7.34

Loading ...

ZCCM-IH Launches Zambia National Energy Corporation to Drive $202m Renewables Rollout

TIPRANKS
·
Jan 19

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

GlobeNewswire
·
Jan 15

Stock Indices Rally Across the Board; IM Main Contract Surges 3.75%

Deep News
·
Jan 12

AE50 2026: ASABE lists three Ag Tech innovations from CNH

GlobeNewswire
·
Jan 07

Take Care Before Jumping Onto iHuman Inc. (NYSE:IH) Even Though It's 26% Cheaper

Simply Wall St.
·
Dec 31, 2025

Stock Track | iHuman Soars 7.07% in Pre-Market on Strong Q3 Results and Strategic Expansions

Stock Track
·
Dec 30, 2025

Stock Track | iHuman Soars 8.76% on Strong Q3 Results and Strategic Expansions

Stock Track
·
Dec 30, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Lululemon, DigitalBridge, Expedia

Reuters
·
Dec 30, 2025

Stock Track | iHuman Soars 6.39% Intraday on Strong Q3 Results and Strategic Expansions

Stock Track
·
Dec 29, 2025

iHuman Reports Q3 2025 Revenue of RMB205.8 Million and Net Profit of RMB21.6 Million

Deep News
·
Dec 29, 2025

iHuman's Q3 revenue falls on lower newborn population

Reuters
·
Dec 29, 2025

iHuman Reported Q3 2025 MAUs Of 26.13M Vs 29.12M YoY

Benzinga
·
Dec 29, 2025

iHuman Q3 Adj. EPS $0.06 Down From $0.07 YoY, Sales $28.900M Down From $34.115M YoY

Benzinga
·
Dec 29, 2025

Press Release: iHuman Inc. Announces Third Quarter 2025 Unaudited Financial Results

Dow Jones
·
Dec 29, 2025

Ihuman Q3 Revenue RMB 205.8 Million

THOMSON REUTERS
·
Dec 29, 2025

Ihuman Q3 Gross Margin 68.3%

THOMSON REUTERS
·
Dec 29, 2025

Ihuman Q3 Operating Expenses RMB 124 Million

THOMSON REUTERS
·
Dec 29, 2025

Ihuman Inc. Announces Third Quarter 2025 Unaudited Financial Results

THOMSON REUTERS
·
Dec 29, 2025

Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia

GlobeNewswire
·
Dec 18, 2025

Press Release: Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

Dow Jones
·
Dec 11, 2025